Veracyte Inc
$ 34.30
5.73%
14 Apr - close price
- Market Cap 2,725,424,000 USD
- Current Price $ 34.30
- High / Low $ 34.48 / 32.42
- Stock P/E 41.83
- Book Value 16.50
- EPS 0.82
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.05 %
- 52 Week High 50.71
- 52 Week Low 22.61
About
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
Analyst Target Price
$46.82
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-04 | 2025-08-06 | 2025-05-05 | 2025-02-20 | 2024-11-06 | 2024-08-06 | 2024-05-07 | 2024-02-22 | 2023-11-07 | 2023-08-08 | 2023-05-04 |
| Reported EPS | 0.53 | 0.51 | 0.44 | 0.31 | 0.36 | 0.19 | 0.07 | -0.02 | -0.39 | -0.41 | -0.12 | -0.11 |
| Estimated EPS | 0.39 | 0.32 | 0.11 | -0.17 | 0.2571 | 0.03 | -0.02 | -0.16 | -0.09 | -0.15 | -0.15 | -0.13 |
| Surprise | 0.14 | 0.19 | 0.33 | 0.48 | 0.1029 | 0.16 | 0.09 | 0.14 | -0.3 | -0.26 | 0.03 | 0.02 |
| Surprise Percentage | 35.8974% | 59.375% | 300% | 282.3529% | 40.0233% | 533.3333% | 450% | 87.5% | -333.3333% | -173.3333% | 20% | 15.3846% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VCYT
2026-04-14 20:39:36
Veracyte (NASDAQ: VCYT) has awarded 44,221 Restricted Stock Units (RSUs) to Kevin Richard Haas, its Chief Development and Technology Officer, as equity compensation. These RSUs, granted on April 10, 2026, come at no cash cost to Haas and will vest 25% on June 2, 2027, with the remaining portion vesting in equal quarterly increments over the subsequent period, contingent on his continued employment. Following this grant, Haas directly holds 44,221 shares of Veracyte Common Stock.
2026-04-14 19:39:36
Veracyte, Inc. (Nasdaq: VCYT) announced it will release its first-quarter 2026 financial results after market close on Tuesday, May 5, 2026. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. A replay of the webcast will be available on Veracyte's investor relations website.
2026-04-14 03:38:56
Veracyte Inc (VCYT) shares rose 4.3% to $32.44 and are considered modestly undervalued, trading 11.6% below their GF Value™ of $36.69. Despite a strong GF Score™ of 85/100, indicating high valuation and growth, the company faces profitability challenges and has seen $3.2 million in insider selling recently. Investors are advised to consider these factors alongside the promising valuation.
2026-04-13 22:39:36
Jefferies has initiated coverage on Veracyte (NASDAQ:VCYT) with a Buy rating and a $45.00 price target, citing the company's profitability and strong diagnostics growth. Veracyte, with its Decipher and Afirma products driving 95% of sales, reported adjusted EBITDA exceeding 25% in 2025 and is expanding into the minimal residual disease market. The stock is considered undervalued by InvestingPro, with analysts setting price targets between $37 and $53.
2026-04-13 15:10:38
Jefferies has initiated coverage of Veracyte (VCYT) with a "Buy" rating and a price target of $45. This endorsement highlights confidence in the company's growth trajectory within the medical diagnostics and research sector. GuruFocus indicates VCYT is currently undervalued with a strong GF Score of 85, suggesting potential for long-term returns despite recent insider sales.
2026-04-13 08:09:26
Jefferies has initiated coverage on Veracyte, Inc. (NASDAQ:VCYT) with a Buy rating and a $45 price target, highlighting the company's profitability and strong growth in its diagnostics platforms. Veracyte demonstrates double-digit testing growth, particularly with its Decipher and Afirma products, and is poised for future expansion into the minimal residual disease market with TrueMRD. The valuation is seen as compelling, with analysts revising earnings upwards and recognizing significant upside potential.
